{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:53:22Z","timestamp":1790618002428,"version":"4.1.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["NIHR203312"],"award-info":[{"award-number":["NIHR203312"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Parkinson's disease is a common neurodegenerative disorder, which is characterised by motor features, many of which relate to the loss of the dopaminergic nigrostriatal pathway. The use of grafted cells to replace the lost dopaminergic neurons as a therapy for Parkinson's has been explored since the 1980s, with mixed clinical outcomes. Much of the heterogeneity in outcomes has been related to the major problems with the cell source for these trials, being derived from human fetal brain tissue. It is, however, now possible to derive authentic midbrain dopamine cells from human pluripotent stem cells and several first-in-human clinical trials are now underway to explore this approach.<\/jats:p>","DOI":"10.1177\/1877718x251397277","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T18:18:37Z","timestamp":1764094717000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical trial highlights: Dopamine cell-replacement therapies"],"prefix":"10.1177","volume":"16","author":[{"given":"Saeed","family":"Kayhanian","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK"},{"name":"Department of Neurosurgery, Cambridge University Hospitals, Cambridge, UK"},{"name":"Cambridge Stem Cell Institute, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK"},{"name":"Cambridge Stem Cell Institute, Cambridge, UK"},{"name":"Department of Neurology, Cambridge University Hospitals, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.5.388"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00400-8"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2105529"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103083441002"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10720"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202400118"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh649"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70295-8"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0507-2"},{"key":"e_1_3_2_11_2","article-title":"The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson\u2019s disease","volume":"2025","author":"Barker RA","year":"2025","unstructured":"Barker RA, Lao-Kaim NP, Guzman NV, et al. The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson\u2019s disease. Nat Biotechnol 2025; 2025: \u20139.","journal-title":"Nat Biotechnol"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2024.12.005"},{"key":"e_1_3_2_13_2","first-page":"1","article-title":"Phase I trial of hES cell-derived dopaminergic neurons for Parkinson\u2019s disease","volume":"11","author":"Tabar V","year":"2025","unstructured":"Tabar V, Sarva H, Lozano AM, et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson\u2019s disease. Nature 2025; 11: 1\u20136.","journal-title":"Nature"},{"key":"e_1_3_2_14_2","unstructured":"BlueRock. Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson\u2019s disease to registrational Phase III clinical trial - BlueRock Therapeutics LP. https:\/\/www.bluerocktx.com\/bluerock-therapeutics-advances-investigational-cell-therapy-bemdaneprocel-for-treating-parkinsons-disease-to-registrational-phase-iii-clinical-trial\/."},{"key":"e_1_3_2_15_2","unstructured":"S.BIOMEDICS Cell Therapy for Parkinson\u2019s Disease Shows Positive Data from Its Phase 1\/2a Clinical Trial | Morningstar. https:\/\/www.morningstar.com\/news\/globe-newswire\/9497581\/sbiomedics-cell-therapy-for-parkinsons-disease-shows-positive-data-from-its-phase-12a-clinical-trial."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915872"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08700-0"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2020.06.002"},{"key":"e_1_3_2_19_2","unstructured":"Aspen Neuroscience Announces Completion of First and Second Cohorts in ASPIRO Phase 1\/2a Trial for Parkinson\u2019s Disease. https:\/\/aspenneuroscience.com\/aspen-neuroscience-announces-completion-of-first-and-second-cohorts-in-aspiro-phase-1-2a-trial-for-parkinsons-disease\/."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2023.08.014"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2023.12.004"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251397277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X251397277","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251397277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:12:26Z","timestamp":1780683146000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X251397277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/1877718X251397277"],"URL":"https:\/\/doi.org\/10.1177\/1877718x251397277","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}